These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 19473422)

  • 1. Revisiting the cost-effectiveness of primary prophylaxis with clotting factor for the treatment of severe haemophilia A.
    Miners A
    Haemophilia; 2009 Jul; 15(4):881-7. PubMed ID: 19473422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
    Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
    Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.
    Henry N; Jovanović J; Schlueter M; Kritikou P; Wilson K; Myrén KJ
    J Med Econ; 2018 Apr; 21(4):318-325. PubMed ID: 29139314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia.
    Miners AH; Sabin CA; Tolley KH; Lee CA
    Pharmacoeconomics; 2002; 20(11):759-74. PubMed ID: 12201795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COST-UTILITY ANALYSIS OF PRIMARY PROPHYLAXIS, COMPARED WITH ON-DEMAND TREATMENT, FOR PATIENTS WITH SEVERE HEMOPHILIA TYPE A IN COLOMBIA.
    Castro Jaramillo HE; Moreno Viscaya M; Mejia AE
    Int J Technol Assess Health Care; 2016 Jan; 32(5):337-347. PubMed ID: 27919309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of late prophylaxis vs. on-demand treatment for severe haemophilia A in Italy.
    Coppola A; D'Ausilio A; Aiello A; Amoresano S; Toumi M; Mathew P; Tagliaferri A;
    Haemophilia; 2017 May; 23(3):422-429. PubMed ID: 28181369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluations of prophylaxis with clotting factor for people with severe haemophilia: why do the results vary so much?
    Miners AH
    Haemophilia; 2013 Mar; 19(2):174-80. PubMed ID: 22989090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment for life for severe haemophilia A- A cost-utility model for prophylaxis vs. on-demand treatment.
    Farrugia A; Cassar J; Kimber MC; Bansal M; Fischer K; Auserswald G; O'Mahony B; Tolley K; Noone D; Balboni S
    Haemophilia; 2013 Jul; 19(4):e228-38. PubMed ID: 23534877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haemophilia A: pharmacoeconomic review of prophylaxis treatment versus on-demand.
    Unim B; Veneziano MA; Boccia A; Ricciardi W; La Torre G
    ScientificWorldJournal; 2015; 2015():596164. PubMed ID: 25685844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of emicizumab prophylaxis in patients with haemophilia A in India.
    Seth T; John MJ; Chakrabarti P; Shanmukhaiah C; Verma SP; Radhakrishnan N; Dolai TK
    Haemophilia; 2024 Mar; 30(2):426-436. PubMed ID: 38147060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of haemophilia treatment: a cross-national assessment.
    Lippert B; Berger K; Berntorp E; Giangrande P; van den Berg M; Schramm W; Siebert U;
    Blood Coagul Fibrinolysis; 2005 Oct; 16(7):477-85. PubMed ID: 16175006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
    Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H
    Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary prophylaxis treatment versus on-demand treatment for patients with severe haemophilia A: comparisons of cost and outcomes in Taiwan.
    Liou WS; Tu TC; Cheng SN; Chou TY; Lee CF; Lin TK; Chung MI; Cham TM
    Haemophilia; 2011 Jan; 17(1):45-54. PubMed ID: 20722742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.
    Valentine WJ; Bottomley JM; Palmer AJ; Brändle M; Foos V; Williams R; Dormandy JA; Yates J; Tan MH; Massi-Benedetti M;
    Diabet Med; 2007 Sep; 24(9):982-1002. PubMed ID: 17593245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of pharmacokinetic-driven prophylaxis vs. standard prophylaxis in patients with severe haemophilia A.
    Iannazzo S; Cortesi PA; Crea R; Steinitz K; Mantovani LG; Gringeri A
    Blood Coagul Fibrinolysis; 2017 Sep; 28(6):425-430. PubMed ID: 27898515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs.
    Tagliaferri A; Franchini M; Coppola A; Rivolta GF; Santoro C; Rossetti G; Feola G; Zanon E; Dragani A; Iannaccaro P; Radossi P; Mannucci PM
    Haemophilia; 2008 Sep; 14(5):945-51. PubMed ID: 18540895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia.
    Thorat T; Neumann PJ; Chambers JD
    J Manag Care Spec Pharm; 2018 Jul; 24(7):632-642. PubMed ID: 29952709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients.
    Lathia N; Isogai PK; De Angelis C; Smith TJ; Cheung M; Mittmann N; Hoch JS; Walker S
    J Natl Cancer Inst; 2013 Aug; 105(15):1078-85. PubMed ID: 23873405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis.
    Grosse SD; Chaugule SS; Hay JW
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):267-83. PubMed ID: 25585817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.